Advagene Biopharma Co., Ltd. (TPEX:6709)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
28.75
-0.75 (-2.54%)
Mar 24, 2026, 1:59 PM CST

Advagene Biopharma Balance Sheet

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
55.3352.8265.1918.0114.33
Short-Term Investments
79.5149.56085209.5
Cash & Short-Term Investments
134.83202.32125.19103.01223.83
Cash Growth
-33.36%61.61%21.54%-53.98%-18.16%
Other Receivables
23.3921.9620.2719.216.59
Receivables
23.3921.9620.2719.216.59
Prepaid Expenses
0.790.540.953.613.57
Total Current Assets
159.01224.82146.41125.82244
Property, Plant & Equipment
76.891.043.225.41
Other Intangible Assets
---9.819.02
Other Long-Term Assets
0.50.50.481.981.98
Total Assets
166.51232.21147.93140.84260.41
Accounts Payable
1.460.750.870.560.56
Accrued Expenses
8.064.75.996.055.79
Current Portion of Leases
1.321.26-1.351.27
Other Current Liabilities
0.780.41.110.460.65
Total Current Liabilities
11.617.117.978.428.27
Long-Term Leases
2.654.56-0.652.57
Total Liabilities
14.2611.677.979.0810.84
Common Stock
593.8593.8533.8493.49492.92
Additional Paid-In Capital
-9060.393.1295.12
Retained Earnings
-441.55-463.26-454.22-364.85-338.47
Shareholders' Equity
152.25220.54139.96131.76249.57
Total Liabilities & Equity
166.51232.21147.93140.84260.41
Total Debt
3.975.82-2.013.84
Net Cash (Debt)
130.87196.5125.19101220
Net Cash Growth
-33.40%56.96%23.95%-54.09%-17.87%
Net Cash Per Share
2.203.602.482.054.51
Filing Date Shares Outstanding
59.3859.3853.3849.3549.29
Total Common Shares Outstanding
59.3859.3853.3849.3549.29
Working Capital
147.4217.72138.44117.39235.72
Book Value Per Share
2.563.712.622.675.06
Tangible Book Value
152.25220.54139.96121.95240.55
Tangible Book Value Per Share
2.563.712.622.474.88
Machinery
2.991.211.361.43.09
Source: S&P Global Market Intelligence. Standard template. Financial Sources.